Morimasa Takayama
Research Subjects
Morimasa Takayama has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Mitsunobu Kitamura
Sakakibara Heart Institute
4 shared publications - Takeshi Yamamoto
Division of Cardiovascular Intensive Care, Nippon Medical School Hospital
4 shared publications Itaru Takamisawa
Hypertrophic Cardiomyopathy Center, Department of Cardiology, Sakakibara Heart Institute , Fuchu
3 shared publications- Junya Matsuda
Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan
3 shared publications - Akito Shindo
Department of Cardiovascular Medicine (H.Y., H.A., Q.L., M.U., H.K., R.M., A.S., S.O., T.U., A.S.-K., K.U., N.T.), Graduate School of Medicine, the University of Tokyo, Japan
2 shared publications - Daisuke Kitano
Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
2 shared publications
Latest Publications
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (6) , e013934
Short-Term Effects of Ambient Temperature on Acute Heart Failure Decompensation: Phenotype-Specific Risk in a Time-Stratified Case-Crossover Study
BACKGROUND: Acute decompensated heart failure (ADHF) exhibits seasonal variations, yet the short-term effects of ambient temperature, independent of seasonality, remain poorly studied. Moreover, temperature-sensitive exacerbation phenotypes are not well defined, limiting the development of effective preventive strategies. We aimed to investigate the effects of ambient temperature on ADHF admissions and clinical presentation profiles. METHODS: We included 26 874 patients with ADHF who had been registered in the Tokyo Cardiovascular Care Unit Network Database between January 2014 and December 2019. The onset date of ADHF leading to hospitalization, along with clinical characteristics such as age, left ventricular function, cause of ADHF, and hemodynamic profile, was assessed by cardiologists at each participating center. Climate data were obtained from an observatory near the admitting hospital. We used a time-stratified case-crossover design with distributed lag nonlinear models to explore the association between ambient temperature and ADHF admissions over lag days 0 to 5, with stratified analyses by the clinical presentations. RESULTS: Exposure to extremely low temperatures (−4.5 °C [first percentile]) increased the risk of ADHF (1.80, 95% CI, 1.40–2.31) when referenced to the temperature of lowest risk (29.0 °C [99th percentile]). The excess risk of lower temperature appeared immediately on the day of exposure (lag 0). This risk was larger in patients aged ≥70 years and otherwise consistent across subgroups. Notably, the temperature-risk relationship differed by hemodynamic profiles; risk for ADHF with hypertension rose at low temperatures, whereas ADHF with low blood pressure showed the opposite pattern, with risk increasing at high temperatures (odds ratio, 6.25 [95% CI, 1.07–36.6] at the 99th percentile). CONCLUSIONS: Low ambient temperature increased ADHF risk, especially in older adults, while temperature effects differed by hemodynamic phenotype. Incorporating temperature exposure into risk assessment may enable targeted prevention of climate-related decompensation. REGISTRATION: URL: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015310 ; Unique identifier: UMIN000013128.
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (6) , e013934
Short-Term Effects of Ambient Temperature on Acute Heart Failure Decompensation: Phenotype-Specific Risk in a Time-Stratified Case-Crossover Study
BACKGROUND: Acute decompensated heart failure (ADHF) exhibits seasonal variations, yet the short-term effects of ambient temperature, independent of seasonality, remain poorly studied. Moreover, temperature-sensitive exacerbation phenotypes are not well defined, limiting the development of effective preventive strategies. We aimed to investigate the effects of ambient temperature on ADHF admissions and clinical presentation profiles. METHODS: We included 26 874 patients with ADHF who had been registered in the Tokyo Cardiovascular Care Unit Network Database between January 2014 and December 2019. The onset date of ADHF leading to hospitalization, along with clinical characteristics such as age, left ventricular function, cause of ADHF, and hemodynamic profile, was assessed by cardiologists at each participating center. Climate data were obtained from an observatory near the admitting hospital. We used a time-stratified case-crossover design with distributed lag nonlinear models to explore the association between ambient temperature and ADHF admissions over lag days 0 to 5, with stratified analyses by the clinical presentations. RESULTS: Exposure to extremely low temperatures (−4.5 °C [first percentile]) increased the risk of ADHF (1.80, 95% CI, 1.40–2.31) when referenced to the temperature of lowest risk (29.0 °C [99th percentile]). The excess risk of lower temperature appeared immediately on the day of exposure (lag 0). This risk was larger in patients aged ≥70 years and otherwise consistent across subgroups. Notably, the temperature-risk relationship differed by hemodynamic profiles; risk for ADHF with hypertension rose at low temperatures, whereas ADHF with low blood pressure showed the opposite pattern, with risk increasing at high temperatures (odds ratio, 6.25 [95% CI, 1.07–36.6] at the 99th percentile). CONCLUSIONS: Low ambient temperature increased ADHF risk, especially in older adults, while temperature effects differed by hemodynamic phenotype. Incorporating temperature exposure into risk assessment may enable targeted prevention of climate-related decompensation. REGISTRATION: URL: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015310 ; Unique identifier: UMIN000013128.
- Open Access
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e044501
Integrating ECG Into the Mayo Score Enhances Genotype Prediction in Hypertrophic Cardiomyopathy
Background: In patients with hypertrophic cardiomyopathy (HCM), genetic testing is crucial for cascade screening and risk stratification. However, it remains limited by financial and logistical constraints, necessitating prioritization. The Mayo HCM Genotype Predictor Score, based on clinical and echocardiographic variables, estimates genotype positivity with acceptable performance. Although sarcomeric variants are also associated with electrophysiological abnormalities, ECG parameters were not incorporated into this model. This study aimed to enhance genotype prediction in HCM by integrating ECG parameters. Methods: We retrospectively analyzed 466 patients with HCM from a Japanese multicenter cohort. Genotype positivity was defined as harboring pathogenic/likely pathogenic variants in sarcomere‐encoding genes. Candidate ECG variables were selected via multivariable logistic regression with bootstrap aggregation. A point‐based novel score was developed and internally validated using cross‐validation. Model performance was assessed by the area under the receiver operating characteristic curve and Akaike’s information criterion. Results: Genotype‐positive patients (30.3%) more frequently exhibited atrial fibrillation, intraventricular conduction disturbance, lower prevalence of high voltage, and abnormal T‐wave inversion in precordial leads than genotype‐negative patients and thus were incorporated into the novel Mayo‐ECG score. This score stratified genotype positivity from 7.1% (score ≤−1) to 91.4% (score ≥4), and its discriminative performance (area under the receiver operating characteristic curve, 0.81 [95% CI, 0.77–0.85]) outperformed the Mayo score (area under the receiver operating characteristic curve, 0.76 [95% CI, 0.71–0.81]; P =0.005) with better overall model fit (Akaike’s information criterion: 439 versus 479). Internal validation yielded consistent results with good calibration. Conclusions: The Mayo‐ECG improves genotype prediction, outperforming the conventional model. Given its simplicity, this model has the potential to prioritize genetic testing in HCM.
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e044501
Open AccessIntegrating ECG Into the Mayo Score Enhances Genotype Prediction in Hypertrophic Cardiomyopathy
Background: In patients with hypertrophic cardiomyopathy (HCM), genetic testing is crucial for cascade screening and risk stratification. However, it remains limited by financial and logistical constraints, necessitating prioritization. The Mayo HCM Genotype Predictor Score, based on clinical and echocardiographic variables, estimates genotype positivity with acceptable performance. Although sarcomeric variants are also associated with electrophysiological abnormalities, ECG parameters were not incorporated into this model. This study aimed to enhance genotype prediction in HCM by integrating ECG parameters. Methods: We retrospectively analyzed 466 patients with HCM from a Japanese multicenter cohort. Genotype positivity was defined as harboring pathogenic/likely pathogenic variants in sarcomere‐encoding genes. Candidate ECG variables were selected via multivariable logistic regression with bootstrap aggregation. A point‐based novel score was developed and internally validated using cross‐validation. Model performance was assessed by the area under the receiver operating characteristic curve and Akaike’s information criterion. Results: Genotype‐positive patients (30.3%) more frequently exhibited atrial fibrillation, intraventricular conduction disturbance, lower prevalence of high voltage, and abnormal T‐wave inversion in precordial leads than genotype‐negative patients and thus were incorporated into the novel Mayo‐ECG score. This score stratified genotype positivity from 7.1% (score ≤−1) to 91.4% (score ≥4), and its discriminative performance (area under the receiver operating characteristic curve, 0.81 [95% CI, 0.77–0.85]) outperformed the Mayo score (area under the receiver operating characteristic curve, 0.76 [95% CI, 0.71–0.81]; P =0.005) with better overall model fit (Akaike’s information criterion: 439 versus 479). Internal validation yielded consistent results with good calibration. Conclusions: The Mayo‐ECG improves genotype prediction, outperforming the conventional model. Given its simplicity, this model has the potential to prioritize genetic testing in HCM.
- Open Access
- 16 January 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (1)
Myocardial testosterone glucuronide and disease phenotypes in hypertrophic cardiomyopathy
Introduction: The relationship between myocardial lipid metabolism and disease phenotypes, genetic variation, and prognostic factors in patients with hypertrophic cardiomyopathy (HCM) remains largely unexplored. This study aimed to clarify how metabolic remodelling relates to disease phenotypes in HCM. We used desorption electrospray ionization imaging mass spectrometry (DESI-IMS) to compare myocardial lipid signatures in patients who required septal reduction therapy (SRT) and those who did not. Methods: In this prospective study, patients with HCM undergoing either right-ventricular biopsy or surgical septal myectomy were enrolled. Frozen 10 µm sections were analysed using DESI-IMS, and mass spectra were compared with volcano plots after signal-intensity normalization. Candidate ions showing |log2 fold change| ≥ 1 and P < .05 were annotated using the Human Metabolome Database. Results: Overall, 61 patients were analysed (34 [55.7%] were female; mean age 64.5 ± 15.9 years). Of these, 43 (70.5%) had obstructive HCM and 20 underwent SRT (SRT, n = 20; non-SRT, n = 41). The SRT group displayed a 3.3-fold higher signal for m/z 463.23, identified as testosterone glucuronide (P < .001). SRT remained the only predictor of elevated testosterone-glucuronide intensity in confirmatory regression (β = 1.991, P = .004), even after adjusting for age at diagnosis and the presence of hypertension, which significantly differed in baseline characteristics between the SRT and non-SRT groups. Conclusion: DESI-IMS revealed selective accumulation of testosterone glucuronide in hypertrophied myocardium from patients needing SRT, suggesting that androgen-linked metabolic remodelling plays a role in advanced obstructive physiology in HCM.
- 16 January 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (1)
Open AccessMyocardial testosterone glucuronide and disease phenotypes in hypertrophic cardiomyopathy
Introduction: The relationship between myocardial lipid metabolism and disease phenotypes, genetic variation, and prognostic factors in patients with hypertrophic cardiomyopathy (HCM) remains largely unexplored. This study aimed to clarify how metabolic remodelling relates to disease phenotypes in HCM. We used desorption electrospray ionization imaging mass spectrometry (DESI-IMS) to compare myocardial lipid signatures in patients who required septal reduction therapy (SRT) and those who did not. Methods: In this prospective study, patients with HCM undergoing either right-ventricular biopsy or surgical septal myectomy were enrolled. Frozen 10 µm sections were analysed using DESI-IMS, and mass spectra were compared with volcano plots after signal-intensity normalization. Candidate ions showing |log2 fold change| ≥ 1 and P < .05 were annotated using the Human Metabolome Database. Results: Overall, 61 patients were analysed (34 [55.7%] were female; mean age 64.5 ± 15.9 years). Of these, 43 (70.5%) had obstructive HCM and 20 underwent SRT (SRT, n = 20; non-SRT, n = 41). The SRT group displayed a 3.3-fold higher signal for m/z 463.23, identified as testosterone glucuronide (P < .001). SRT remained the only predictor of elevated testosterone-glucuronide intensity in confirmatory regression (β = 1.991, P = .004), even after adjusting for age at diagnosis and the presence of hypertension, which significantly differed in baseline characteristics between the SRT and non-SRT groups. Conclusion: DESI-IMS revealed selective accumulation of testosterone glucuronide in hypertrophied myocardium from patients needing SRT, suggesting that androgen-linked metabolic remodelling plays a role in advanced obstructive physiology in HCM.
- 17 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (3) , 212-219
Value of plasma D-dimer level for prediction of in-hospital mortality in patients presenting with Takotsubo syndrome
Aims: D-dimer, degradation product of cross-linked fibrin, has been described as the prognostic marker in some cardiovascular diseases. However, the association between D-dimer levels and prognosis has not been fully evaluated in patients with Takotsubo syndrome (TTS). Methods and results: We retrospectively analysed data of 580 patients with TTS from the Tokyo Cardiovascular Care Unit Network registry. The primary endpoint was in-hospital all-cause death. Logistic regression analysis was used to investigate the relationship between D-dimer level and mortality. The additive effect of D-dimer level on the conventional prognostic risk score (InterTAK) was assessed using C-statistic, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). In the entire sample (median age, 77 years; 79.5% women), 174 (30.0%) patients had an emotional trigger, while 177 (30.5%) patients had a physical trigger, causing 28 (4.8%) deaths (cardiac death [n = 13, 46.4%], non-cardiac death [n = 15, 53.6%]). D-dimer levels on admission were significantly higher in those who died than in those who survived (6.4 [3.9–18.3] vs. 1.1 [0.7–2.9] µg/mL, P < 0.001). On multivariable logistic regression analysis, the odds ratio (OR) for in-hospital mortality significantly increased with D-dimer levels ≥3.5 µg/mL (OR: 7.06 [95% confidence interval: 2.90–17.16], P < 0.001). The InterTAK Prognostic Score was 17 (11–24), and NRI and IDI were improved by incorporating D-dimer levels (NRI: 1.08, P < 0.001; IDI: 0.05, P < 0.001). Conclusion: Elevated D-dimer levels may serve as an additional predictor of increased in-hospital mortality in patients with TTS. Patients with higher D-dimer levels may warrant intensified monitoring and management.
- 17 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (3) , 212-219
Value of plasma D-dimer level for prediction of in-hospital mortality in patients presenting with Takotsubo syndrome
Aims: D-dimer, degradation product of cross-linked fibrin, has been described as the prognostic marker in some cardiovascular diseases. However, the association between D-dimer levels and prognosis has not been fully evaluated in patients with Takotsubo syndrome (TTS). Methods and results: We retrospectively analysed data of 580 patients with TTS from the Tokyo Cardiovascular Care Unit Network registry. The primary endpoint was in-hospital all-cause death. Logistic regression analysis was used to investigate the relationship between D-dimer level and mortality. The additive effect of D-dimer level on the conventional prognostic risk score (InterTAK) was assessed using C-statistic, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). In the entire sample (median age, 77 years; 79.5% women), 174 (30.0%) patients had an emotional trigger, while 177 (30.5%) patients had a physical trigger, causing 28 (4.8%) deaths (cardiac death [n = 13, 46.4%], non-cardiac death [n = 15, 53.6%]). D-dimer levels on admission were significantly higher in those who died than in those who survived (6.4 [3.9–18.3] vs. 1.1 [0.7–2.9] µg/mL, P < 0.001). On multivariable logistic regression analysis, the odds ratio (OR) for in-hospital mortality significantly increased with D-dimer levels ≥3.5 µg/mL (OR: 7.06 [95% confidence interval: 2.90–17.16], P < 0.001). The InterTAK Prognostic Score was 17 (11–24), and NRI and IDI were improved by incorporating D-dimer levels (NRI: 1.08, P < 0.001; IDI: 0.05, P < 0.001). Conclusion: Elevated D-dimer levels may serve as an additional predictor of increased in-hospital mortality in patients with TTS. Patients with higher D-dimer levels may warrant intensified monitoring and management.
- 1 March 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (3) , e011270
Hospital Variability in the Use of Vasoactive Agents in Patients Hospitalized for Acute Decompensated Heart Failure for Clinical Phenotypes
BACKGROUND: The absence of practice standards in vasoactive agent usage for acute decompensated heart failure has resulted in significant treatment variability across hospitals, potentially affecting patient outcomes. This study aimed to assess temporal trends and institutional differences in vasodilator and inotrope/vasopressor utilization among patients with acute decompensated heart failure, considering their clinical phenotypes. METHODS: Data were extracted from a government-funded multicenter registry covering the Tokyo metropolitan area, comprising consecutive patients hospitalized in intensive/cardiovascular care units with a primary diagnosis of acute decompensated heart failure between January 2013 and December 2021. Clinical phenotypes, that is, pulmonary congestion or tissue hypoperfusion, were defined through a comprehensive assessment of clinical signs and symptoms, vital signs, and laboratory findings. We assessed the frequency and temporal trends in phenotype-based drug utilization of vasoactive agents and investigated institutional characteristics associated with adopting the phenotype-based approach using generalized linear mixed-effects models, with random intercepts to account for hospital-level variability. RESULTS: Among 37 293 patients (median age, 80 years; 43.7% female), 88.6% and 21.2% had pulmonary congestion and tissue hypoperfusion status, respectively. Throughout the study period, both overall and phenotype-based vasodilator utilizations showed significant declines, with overall usage dropping from 61.4% in 2013 to 48.6% in 2021 ( P trend <0.001). Conversely, no temporal changes were observed in overall inotrope/vasopressor utilization from 24.6% in 2013 to 25.8% in 2021 or the proportion of phenotype-based utilization. Notably, there was considerable variability in phenotype-based drug utilization among hospitals, with a median ranging from 48.3% to 77.8%. In multivariable-adjusted models, a higher number of board-certified cardiologists were significantly associated with lower rates of phenotype-based vasodilator utilization and reduced inappropriate inotrope/vasopressor utilization, while tertiary care hospitals were linked to more appropriate inotrope/vasopressor utilization. CONCLUSIONS: Substantial variability existed among hospitals in phenotype-based drug utilization of vasoactive agents for patients with acute decompensated heart failure, highlighting the need for standardized treatment protocols. REGISTRATION: URL: https://www.umin.ac.jp/ctr/index.htm ; Unique identifier: UMIN000013128.
- 1 March 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (3) , e011270
Hospital Variability in the Use of Vasoactive Agents in Patients Hospitalized for Acute Decompensated Heart Failure for Clinical Phenotypes
BACKGROUND: The absence of practice standards in vasoactive agent usage for acute decompensated heart failure has resulted in significant treatment variability across hospitals, potentially affecting patient outcomes. This study aimed to assess temporal trends and institutional differences in vasodilator and inotrope/vasopressor utilization among patients with acute decompensated heart failure, considering their clinical phenotypes. METHODS: Data were extracted from a government-funded multicenter registry covering the Tokyo metropolitan area, comprising consecutive patients hospitalized in intensive/cardiovascular care units with a primary diagnosis of acute decompensated heart failure between January 2013 and December 2021. Clinical phenotypes, that is, pulmonary congestion or tissue hypoperfusion, were defined through a comprehensive assessment of clinical signs and symptoms, vital signs, and laboratory findings. We assessed the frequency and temporal trends in phenotype-based drug utilization of vasoactive agents and investigated institutional characteristics associated with adopting the phenotype-based approach using generalized linear mixed-effects models, with random intercepts to account for hospital-level variability. RESULTS: Among 37 293 patients (median age, 80 years; 43.7% female), 88.6% and 21.2% had pulmonary congestion and tissue hypoperfusion status, respectively. Throughout the study period, both overall and phenotype-based vasodilator utilizations showed significant declines, with overall usage dropping from 61.4% in 2013 to 48.6% in 2021 ( P trend <0.001). Conversely, no temporal changes were observed in overall inotrope/vasopressor utilization from 24.6% in 2013 to 25.8% in 2021 or the proportion of phenotype-based utilization. Notably, there was considerable variability in phenotype-based drug utilization among hospitals, with a median ranging from 48.3% to 77.8%. In multivariable-adjusted models, a higher number of board-certified cardiologists were significantly associated with lower rates of phenotype-based vasodilator utilization and reduced inappropriate inotrope/vasopressor utilization, while tertiary care hospitals were linked to more appropriate inotrope/vasopressor utilization. CONCLUSIONS: Substantial variability existed among hospitals in phenotype-based drug utilization of vasoactive agents for patients with acute decompensated heart failure, highlighting the need for standardized treatment protocols. REGISTRATION: URL: https://www.umin.ac.jp/ctr/index.htm ; Unique identifier: UMIN000013128.
- 10 January 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (11) , 1079
Diagnostic utility of respiratory chain enzyme analysis in isolated mitochondrial cardiomyopathy mimicking hypertrophic cardiomyopathy
- 10 January 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (11) , 1079
Diagnostic utility of respiratory chain enzyme analysis in isolated mitochondrial cardiomyopathy mimicking hypertrophic cardiomyopathy
- Open Access
- 1 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (9) , ytae485
Microcatheter-facilitated alcohol septal ablation for residual left ventricular outflow tract obstruction
A 65-year-old female patient with obstructive hypertrophic cardiomyopathy was referred to our hospital for septal reduction therapy. Echocardiography revealed left ventricular outflow tract obstruction (LVOTO) with systolic anterior motion of the mitral leaflet and no abnormal structure related to the obstruction. Coronary angiography identified the major septal branch originating from the left anterior descending artery to be a target branch for alcohol septal ablation (ASA) (Panel A). In the initial procedure, under septal branch occlusion by a 2 mm over-the-wire balloon (see Movie S1), the culprit myocardial bulge was ablated with 2 mL of ethanol (Panels B and C), with the resting gradient reduced from 100 to 3 mmHg and peak serum creatine kinase level of 1330 U/L. One year later, exertional dyspnoea recurred with LVOTO at the most-basal septum. In coronary angiography, a sub-branch from the left circumflex artery was deemed to be a target vessel for ASA (Panel D). In the repeat procedure, we used a Corsair Pro microcatheter [tip: 1.3 Fr (0.42 mm), shaft: 2.6 Fr (0.87 mm), Asahi Intec, Nagoya, Japan]. A tip-injection into the microcatheter wedged on the sub-branch confirmed the perfusion to the culprit basal septum and no ethanol leakage to any other vessel (Panel E, Movie S2). Injection of 1.2 mL of ethanol resulted in ablation of the residual myocardial bulge (Panel F). The gradient reduced from 42 to 2 mmHg at rest and 87 to 6 mmHg on Valsalva with peak serum creatine kinase level of 453 U/L. Cardiac magnetic resonance imaging proved the additional ablation of the most-basal septum (Panels G and H, arrowheads) next to the scar of the initial ASA (Panels G and I, arrows). No relapse of LVOTO was observed for three-year follow-up.
- 1 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (9) , ytae485
Open AccessMicrocatheter-facilitated alcohol septal ablation for residual left ventricular outflow tract obstruction
A 65-year-old female patient with obstructive hypertrophic cardiomyopathy was referred to our hospital for septal reduction therapy. Echocardiography revealed left ventricular outflow tract obstruction (LVOTO) with systolic anterior motion of the mitral leaflet and no abnormal structure related to the obstruction. Coronary angiography identified the major septal branch originating from the left anterior descending artery to be a target branch for alcohol septal ablation (ASA) (Panel A). In the initial procedure, under septal branch occlusion by a 2 mm over-the-wire balloon (see Movie S1), the culprit myocardial bulge was ablated with 2 mL of ethanol (Panels B and C), with the resting gradient reduced from 100 to 3 mmHg and peak serum creatine kinase level of 1330 U/L. One year later, exertional dyspnoea recurred with LVOTO at the most-basal septum. In coronary angiography, a sub-branch from the left circumflex artery was deemed to be a target vessel for ASA (Panel D). In the repeat procedure, we used a Corsair Pro microcatheter [tip: 1.3 Fr (0.42 mm), shaft: 2.6 Fr (0.87 mm), Asahi Intec, Nagoya, Japan]. A tip-injection into the microcatheter wedged on the sub-branch confirmed the perfusion to the culprit basal septum and no ethanol leakage to any other vessel (Panel E, Movie S2). Injection of 1.2 mL of ethanol resulted in ablation of the residual myocardial bulge (Panel F). The gradient reduced from 42 to 2 mmHg at rest and 87 to 6 mmHg on Valsalva with peak serum creatine kinase level of 453 U/L. Cardiac magnetic resonance imaging proved the additional ablation of the most-basal septum (Panels G and H, arrowheads) next to the scar of the initial ASA (Panels G and I, arrows). No relapse of LVOTO was observed for three-year follow-up.
- Open Access
- 25 July 2019
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 83 (8) , 1755-1761
Usefulness of the Transcatheter Aortic Valve Replacement Risk Score to Determine Mid-Term Outcomes
Background:The purpose of this study was to investigate if the transcatheter aortic valve replacement (TAVR) risk score can independently predict outcomes following TAVR, and to evaluate its predictive performance.Methods and Results:This retrospective multicenter study comprised 682 patients with severe aortic stenosis who underwent TAVR. The primary endpoint was all-cause death following TAVR. The clinical model was established using variables identified as independent predictors in the multivariate analysis. Incremental values were assessed after adding atrial fibrillation, body mass index (BMI), and serum albumin to the TAVR risk score in receiver-operating characteristic analysis. The median TAVR risk score was 2.1% with a mean follow-up of 505 days. On Kaplan-Meier analysis, a TAVR risk score >4% had lowest survival rate, whereas TAVR risk score ≤2% had the highest survival rate at 3 years (log-rank P<0.001). The multivariate Cox regression analysis found the TAVR risk score was independently associated with all-cause death, and demonstrated moderate predictive performance for predicting all-cause death at 3 years. However, if each independent predictor is added to the model, it significantly increased discriminatory performance, particularly with BMI and serum albumin level.Conclusions:We demonstrated that the TAVR risk score could independently predict mid-term death following TAVR, and had greater predictive performance for predicting all-cause death at 3 years with BMI and serum albumin level.
- 25 July 2019
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 83 (8) , 1755-1761
Open AccessUsefulness of the Transcatheter Aortic Valve Replacement Risk Score to Determine Mid-Term Outcomes
Background:The purpose of this study was to investigate if the transcatheter aortic valve replacement (TAVR) risk score can independently predict outcomes following TAVR, and to evaluate its predictive performance.Methods and Results:This retrospective multicenter study comprised 682 patients with severe aortic stenosis who underwent TAVR. The primary endpoint was all-cause death following TAVR. The clinical model was established using variables identified as independent predictors in the multivariate analysis. Incremental values were assessed after adding atrial fibrillation, body mass index (BMI), and serum albumin to the TAVR risk score in receiver-operating characteristic analysis. The median TAVR risk score was 2.1% with a mean follow-up of 505 days. On Kaplan-Meier analysis, a TAVR risk score >4% had lowest survival rate, whereas TAVR risk score ≤2% had the highest survival rate at 3 years (log-rank P<0.001). The multivariate Cox regression analysis found the TAVR risk score was independently associated with all-cause death, and demonstrated moderate predictive performance for predicting all-cause death at 3 years. However, if each independent predictor is added to the model, it significantly increased discriminatory performance, particularly with BMI and serum albumin level.Conclusions:We demonstrated that the TAVR risk score could independently predict mid-term death following TAVR, and had greater predictive performance for predicting all-cause death at 3 years with BMI and serum albumin level.
- Open Access
- 1 January 2018
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 82 (4) , 1062-1069
High Signal Intensity on T2-Weighted Cardiovascular Magnetic Resonance Imaging Predicts Life-Threatening Arrhythmic Events in Hypertrophic Cardiomyopathy Patients
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2018
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 82 (4) , 1062-1069
Open AccessHigh Signal Intensity on T2-Weighted Cardiovascular Magnetic Resonance Imaging Predicts Life-Threatening Arrhythmic Events in Hypertrophic Cardiomyopathy Patients
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies